Burnham urged to ditch ‘dangerous’ UK-US NHS drug deal

Health groups are pressuring Andy Burnham to reject a controversial UK-US trade deal on medicines, arguing it could result in 229,000 excess deaths by 2036. They claim the agreement prioritizes pharmaceutical profits over patient safety, while ministers defend it as a means to boost British drug exports and avoid tariffs. This debate highlights the tension between international trade agreements and public health, raising questions about the balance between economic benefits and healthcare priorities.